Teva's 4th-qtr profits up 42%, but EPS falls short
Israeli generic drugmaker Teva Pharmaceuticals says that, for the quarter ended December 31, its net income was $433.0 million, up 42% on the comparable period of 2005. The firm also reported that its earnings per share had increased 18% to $0.53, which was short of the $0.58 per share predicted by analysts questioned in a Thompson Financial survey.
Observers said that the EPS shortfall was due to the contraction of the company's gross margins in the second and third quarters following its loss of US Food and Drug Administration exclusivity rights to key products.
Sales up 63% to $2.3 billion
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze